NNNN
Anbio Biotechnology Class A Ordinary Shares
NASDAQ · Healthcare · Medical - Instruments & Supplies · DE
$6.55
−0.76%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 14.3M | 8.6M | 8.2M | 6.7M | 23.5M |
| Cost of Revenue | 2.0M | 1.1M | 2.3M | 3.4M | 11.0M |
| Gross Profit | 12.3M | 7.5M | 5.9M | 3.4M | 12.6M |
| Operating Expenses | |||||
| R&D Expense | 613.5K | 201.3K | 454.2K | 134.7K | 200.0K |
| SG&A Expense | 5.7M | 1.6M | 3.4M | 1.3M | 2.2M |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 1.00 | — | — | — | — |
| Total Operating Expenses | 6.3M | 1.8M | 3.9M | 1.4M | 2.4M |
| Cost and Expenses | (165.0K) | 2.9M | 6.2M | 4.8M | 13.3M |
| Operating Income (EBIT) | 5.9M | 5.8M | 2.0M | 2.0M | 10.2M |
| Non-Operating | |||||
| Interest Income | 405.6K | 142.0K | 337.5K | 165.3K | 42.2K |
| Interest Expense | — | — | — | — | 8.0K |
| Net Interest Income | 405.6K | 142.0K | 337.5K | 165.3K | 34.2K |
| Other Non-Op Income/Expense | 1.2M | 635.7K | 377.5K | 292.8K | (184.4K) |
| Non-Operating Income (excl Interest) | (410.5K) | — | — | (292.8K) | 176.4K |
| EBT (Pre-Tax Income) | 7.2M | 6.4M | 2.4M | 2.3M | 10.0M |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | 7.2M | 6.4M | 2.4M | 2.3M | 10.0M |
| Earnings from Cont. Ops | 7.2M | 6.4M | 2.4M | 2.3M | 10.0M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 7.2M | 6.4M | 2.4M | 2.3M | 10.0M |
| Per Share | |||||
| Basic EPS | $0.16 | $0.16 | $0.06 | $0.02 | $0.07 |
| Diluted EPS | $0.16 | $0.16 | $0.06 | $0.01 | $0.07 |
| Revenue Per Share | $0.33 | $0.20 | $0.19 | $0.05 | $0.16 |
| Shares | |||||
| Basic Shares Outstanding | 43.9M | 43.9M | 42.3M | 143.9M | 143.9M |
| Diluted Shares Outstanding | 43.9M | 43.9M | 42.3M | 187.8M | 143.9M |
| Profitability Metrics | |||||
| EBITDA | 5.2M | 5.8M | 2.0M | 2.3M | 10.0M |
| D&A | (1.2M) | — | — | 13.0K | 6.3K |
| EBIT | 6.4M | 5.8M | 2.0M | 2.3M | 10.0M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Dec 1, 2025